# Next session — pickup notes

Last touched: 2026-05-06. Branch `main`.

## What landed this session

Built `scripts/build_graph.py` — an end-to-end driver that fetches trials,
populates the graph, annotates, and attributes in one command. Along the
way we made the graph trial-driven instead of catalog-driven: OT lookups
now pull only the targets bound by trial compounds (~19 vs ~955 before),
mechanisms are inferred per trial, BiologyNodes are auto-created (Reactome
when LINCS hits, `{mechanism}__{indication}` slug otherwise), subgroup
PopulationNodes are seeded from extraction.subgroups and chains are
forked across them, the classifier prompt is entity-grounded (uses
canonical node IDs from the trial's subgraph), AE attribution actually
works, and Phase-I safety/vitals/labs route to a `safety` endpoint class
deterministically. At n=10 melanoma the graph is 158 nodes / 239 edges
with every causal-chain edge type populated.

## Where to start next time — n=100 run

```bash
# Wipe and run full pipeline at n=100 melanoma
rm -f data/exports/oncology_*.json data/annotations/*.json
.venv/bin/python -m scripts.build_graph --condition melanoma --max-trials 100
```

Cost note: ~100 extractions + ~100 classifications (Sonnet) + ~30–50 OT
drug lookups + ~100 mechanism inferences (Haiku). Most structural
classifications hit `data/cache/` so reruns are cheap.

To iterate on attribute-only changes after a run, use:
```bash
.venv/bin/python -m scripts.build_graph --condition melanoma --max-trials 100 --keep-annotations
```

## Open follow-ups (skipped at n=10, may matter at n=100)

- `reflects_biology` edges (biology→endpoint) are never seeded; they'd
  need biomarker-validation data we don't have yet. Skipped intentionally.
- `subgroup_taxonomy.canonicalize_feature` falls back to `axis="other"`
  for response strata (CR/PR/SD/PD) and continuous biomarkers, producing
  messy PopulationNode ids like `melanoma__other_complete_response`.
  Worth tightening if subgroup quality matters at n=100.
- `_populate_compound_targets` picks the first OT drug-search hit; fine
  for well-known drugs, may pick wrong target for ambiguous names.
- One trial in our n=10 (NCT00162123) has no primary outcome that
  resolves to an endpoint — gets skipped during attribution. Expect a
  small number of similar skips at n=100.
